Listed

Quest Diagnostics Inc: Form 10-Q for the period ended Sep 30, 2020

Filed with the SEC on Oct 23, 2020 and accepted by EDGAR at Oct 23, 2020, 16:08 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-07-01 to 2020-09-30$2.79bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2020-01-01 to 2020-09-30$6.43bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2020-07-01 to 2020-09-30$1.58bnus-gaap:CostOfRevenue
Cost of revenue9 months2020-01-01 to 2020-09-30$4.07bnus-gaap:CostOfRevenue
Selling, general and administrative3 months2020-07-01 to 2020-09-30$396.0mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2020-01-01 to 2020-09-30$1.10bnus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2020-07-01 to 2020-09-30$718.0mus-gaap:OperatingIncomeLoss
Operating income9 months2020-01-01 to 2020-09-30$1.18bnus-gaap:OperatingIncomeLoss
Interest expense3 months2020-07-01 to 2020-09-30$42.0mus-gaap:InterestExpense
Interest expense9 months2020-01-01 to 2020-09-30$126.0mus-gaap:InterestExpense
Income tax3 months2020-07-01 to 2020-09-30$177.0mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2020-01-01 to 2020-09-30$269.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2020-07-01 to 2020-09-30$568.0mus-gaap:NetIncomeLoss
Net income9 months2020-01-01 to 2020-09-30$852.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2020-07-01 to 2020-09-30$4.14us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2020-01-01 to 2020-09-30$6.25us-gaap:EarningsPerShareDiluted
Basic EPS3 months2020-07-01 to 2020-09-30$4.20us-gaap:EarningsPerShareBasic
Basic EPS9 months2020-01-01 to 2020-09-30$6.33us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2020-07-01 to 2020-09-30137,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2020-01-01 to 2020-09-30136,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2020-01-01 to 2020-09-30$1.46bnus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2020-01-01 to 2020-09-30$256.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid9 months2020-01-01 to 2020-09-30$222.0mus-gaap:PaymentsOfDividendsCommonStock
Share repurchases9 months2020-01-01 to 2020-09-30$75.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2020-09-30$1.60bnus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-09-30$3.35bnus-gaap:AssetsCurrent
Total assetsAt period end2020-09-30$14.14bnus-gaap:Assets
Current liabilitiesAt period end2020-09-30$2.39bnus-gaap:LiabilitiesCurrent
Long-term debtAt period end2020-09-30$4.02bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2020-09-30$555.0mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2020-09-30$6.40bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001022079-20-000185. Last ingested by Listed: Nov 13, 2026, 17:16 ET. Listed shows no prices and gives no investment advice.